Gain Therapeutics
GANX
25 hedge funds and large institutions have $7.68M invested in Gain Therapeutics in 2024 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 4 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 2
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
104% more call options, than puts
Call options by funds: $47K | Put options by funds: $23K
32% more funds holding
Funds holding: 19 → 25 (+6)
0.92% more ownership
Funds ownership: 6.56% → 7.48% (+0.92%)
21% less capital invested
Capital invested by funds: $9.77M → $7.68M (-$2.09M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$184K |
| 2 |
Morgan Stanley
New York
|
+$168K |
| 3 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$109K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$94.2K |
| 5 |
Jones Financial Companies
Des Peres,
Missouri
|
+$89.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GAM
Gotham Asset Management
New York
|
-$354K |
| 2 |
Renaissance Technologies
New York
|
-$94.8K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
-$9.64K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$9.13K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$8.62K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Renaissance Technologies
New York
| – | -$94.8K | -53,264 | Closed |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| – | -$8.62K | -4,842 | Closed |
|
|
28
Simplex Trading
Chicago,
Illinois
| – | -$9.64K | -4,801 | Closed |
|
29
Group One Trading
Chicago,
Illinois
| – | -$2.81K | -1,401 | Closed |
|
GANX Hedge Fund Activity: Q4 2024 in Review
25 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Gain Therapeutics (GANX) for Q4 2024, worth a combined $7.68M — down 21% from $9.77M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new GANX positions and 4 closed out — a net gain of 6 holders — while 8 added to existing stakes and 2 trimmed.
The largest buyer was Marshall Wace, opening a new position worth an estimated $184K. The largest seller was Gotham Asset Management, cutting an estimated $354K.
- 25 institutional investors held Gain Therapeutics (GANX) as of Q4 2024, up from 19 in Q3 2024.
- Funds reported $7.68M of Gain Therapeutics stock for Q4 2024, down 21% quarter-over-quarter.
- 10 funds opened new Gain Therapeutics positions in Q4 2024 and 4 closed out, a net change of +6 holders.
- The largest Gain Therapeutics buyer in Q4 2024 was Marshall Wace, an estimated $184K added.
- The largest Gain Therapeutics seller in Q4 2024 was Gotham Asset Management, an estimated $354K sold.
Based on aggregated 13F filings for Q4 2024.